Long acting injectable Cabotegravir for PrEP is in Phase 3 [every 4 or 8 weeks]
Long acting injectable Cabotegravir for PrEP is in Phase 3 [every 4 or 8 weeks] so this is the closest in terms of reality, for a major impact of long-acting drugs with a potential to impact HIV & AIDS, but in the area of PrEP. Increasingly over the past few years we have been hearing about nano technology and about implants which would be long acting and have the added characteristic that the implant could be removed at any time, this helps regarding if adverse events occur related to the drug in question.
